Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

• Lei Xu,
• Razvan Cristescu,
• Jared Lunceford,
• Andrey Loboda,
• Andrew Albright,
• Xiao Qiao Liu,
• Alexandra Snyder,
• Fan Jin,
• Lixin Lang,
• Deepti Aurora-Garg,
• Eric H Rubin

Affiliations

Lei Xu

Merck & Co, Inc, Kenilworth, New Jersey, USA

Razvan Cristescu

Merck & Co, Inc, Kenilworth, New Jersey, USA

Jared Lunceford

Merck & Co, Inc, Kenilworth, New Jersey, USA

Andrey Loboda

Merck & Co, Inc, Kenilworth, New Jersey, USA

Andrew Albright

Merck & Co, Inc, Kenilworth, New Jersey, USA

Xiao Qiao Liu

MSD China, Beijing, China

Alexandra Snyder

Merck & Co, Inc, Kenilworth, New Jersey, USA

Fan Jin

Merck & Co, Inc, Kenilworth, New Jersey, USA

Lixin Lang

Merck & Co, Inc, Kenilworth, New Jersey, USA

Deepti Aurora-Garg

Merck & Co, Inc, Kenilworth, New Jersey, USA

Eric H Rubin

Merck & Co, Inc, Kenilworth, New Jersey, USA